{"id":534313,"date":"2021-09-03T08:31:01","date_gmt":"2021-09-03T12:31:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-reports-financial-results-and-recent-business-highlights-for-first-quarter-fiscal-year-2022\/"},"modified":"2021-09-03T08:31:01","modified_gmt":"2021-09-03T12:31:01","slug":"immunoprecise-reports-financial-results-and-recent-business-highlights-for-first-quarter-fiscal-year-2022","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-reports-financial-results-and-recent-business-highlights-for-first-quarter-fiscal-year-2022\/","title":{"rendered":"ImmunoPrecise Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2022"},"content":{"rendered":"

<\/p>\n

ImmunoPrecise Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2022<\/b><\/p>\n

The Company to host an earnings conference call via webcast on September 9, 2021, at the close of market<\/i><\/p>\n

VICTORIA, British Columbia–(BUSINESS WIRE<\/a>)–
\nIMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced that it will host a conference call to discuss its financial results and recent business highlights for first quarter fiscal year 2022, on September 9, 2021, after the close of market. The financial results will be issued in a press release prior to the call. ImmunoPrecise management will host the conference call followed by a pre-submitted question-and-answer period. Investors interested in submitting questions ahead of the call are encouraged to email the Company\u2019s investor relations representative.\n<\/p>\n

Conference Call:<\/b><\/p>\n

Date:<\/b> September 9, 2021
\n
Time:<\/b> 4:30 p.m. Eastern time
\n
Toll-free dial-in number:<\/b> 1-877-407-3982
\n
International dial-in number:<\/b> 1-201-493-6780
\n
Conference ID:<\/b> 13722893
\n
Webcast:<\/b>http:\/\/public.viavid.com\/index.php?id=146463<\/a><\/p>\n

\nThe conference call will be webcast live and available for replay via a link provided in the Events section of the company\u2019s IR pages at https:\/\/www.immunoprecise.com\/investors<\/a>.\n<\/p>\n

\nPlease call the conference telephone number five minutes prior to the start time. An operator will register your name and organization.\n<\/p>\n

\nAnyone listening to the call is encouraged to read the company’s periodic reports on file with the Toronto Stock Exchange and Securities and Exchange Commission, including the discussion of risk factors and historical results of operations and financial condition in those reports.\n<\/p>\n

\n

ImmunoPrecise Antibodies Ltd.<\/b><\/p>\n

\nImmunoPrecise is an innovation-driven technology platform company that supports its business partners in their quest to discover and develop novel antibodies against a broad range of classes of disease targets. The Company aims to transform the conventional multi-vendor antibody discovery model by providing a comprehensive suite of services tailored to optimize antibody genetic diversity and epitope coverage, to discover antibodies against rare and\/or challenging epitopes. For further information, visit www.immunoprecise.com<\/a>.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210903005055\/en\/<\/a><\/span><\/p>\n

Investors:
\n<\/b>
LifeSci Advisors
\n<\/b>
John Mullaly
\n
Email: jmullaly@lifesciadvisors.com<\/a><\/p>\n

KEYWORDS:<\/b> United States North America Canada<\/p>\n

INDUSTRY KEYWORDS:<\/b> Health Infectious Diseases Genetics Research Science Pharmaceutical Biotechnology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

ImmunoPrecise Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2022 The Company to host an earnings conference call via webcast on September 9, 2021, at the close of market VICTORIA, British Columbia–(BUSINESS WIRE)– IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced that it will host a conference call to discuss its financial results and recent business highlights for first quarter fiscal year 2022, on September 9, 2021, after the close of market. The financial results will be issued in a press release prior to the call. ImmunoPrecise management will host the conference call followed by a pre-submitted question-and-answer period. Investors interested … <\/p>\n

Continue reading “ImmunoPrecise Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2022”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-534313","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nImmunoPrecise Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2022 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-reports-financial-results-and-recent-business-highlights-for-first-quarter-fiscal-year-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ImmunoPrecise Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2022 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ImmunoPrecise Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2022 The Company to host an earnings conference call via webcast on September 9, 2021, at the close of market VICTORIA, British Columbia–(BUSINESS WIRE)– IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced that it will host a conference call to discuss its financial results and recent business highlights for first quarter fiscal year 2022, on September 9, 2021, after the close of market. The financial results will be issued in a press release prior to the call. ImmunoPrecise management will host the conference call followed by a pre-submitted question-and-answer period. Investors interested … Continue reading "ImmunoPrecise Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2022"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-reports-financial-results-and-recent-business-highlights-for-first-quarter-fiscal-year-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-03T12:31:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210903005055r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-reports-financial-results-and-recent-business-highlights-for-first-quarter-fiscal-year-2022\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-reports-financial-results-and-recent-business-highlights-for-first-quarter-fiscal-year-2022\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ImmunoPrecise Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2022\",\"datePublished\":\"2021-09-03T12:31:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-reports-financial-results-and-recent-business-highlights-for-first-quarter-fiscal-year-2022\\\/\"},\"wordCount\":387,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-reports-financial-results-and-recent-business-highlights-for-first-quarter-fiscal-year-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210903005055r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-reports-financial-results-and-recent-business-highlights-for-first-quarter-fiscal-year-2022\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-reports-financial-results-and-recent-business-highlights-for-first-quarter-fiscal-year-2022\\\/\",\"name\":\"ImmunoPrecise Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2022 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-reports-financial-results-and-recent-business-highlights-for-first-quarter-fiscal-year-2022\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-reports-financial-results-and-recent-business-highlights-for-first-quarter-fiscal-year-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210903005055r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2021-09-03T12:31:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-reports-financial-results-and-recent-business-highlights-for-first-quarter-fiscal-year-2022\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-reports-financial-results-and-recent-business-highlights-for-first-quarter-fiscal-year-2022\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-reports-financial-results-and-recent-business-highlights-for-first-quarter-fiscal-year-2022\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210903005055r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210903005055r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-reports-financial-results-and-recent-business-highlights-for-first-quarter-fiscal-year-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ImmunoPrecise Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ImmunoPrecise Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2022 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-reports-financial-results-and-recent-business-highlights-for-first-quarter-fiscal-year-2022\/","og_locale":"en_US","og_type":"article","og_title":"ImmunoPrecise Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2022 - Market Newsdesk","og_description":"ImmunoPrecise Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2022 The Company to host an earnings conference call via webcast on September 9, 2021, at the close of market VICTORIA, British Columbia–(BUSINESS WIRE)– IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced that it will host a conference call to discuss its financial results and recent business highlights for first quarter fiscal year 2022, on September 9, 2021, after the close of market. The financial results will be issued in a press release prior to the call. ImmunoPrecise management will host the conference call followed by a pre-submitted question-and-answer period. Investors interested … Continue reading \"ImmunoPrecise Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2022\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-reports-financial-results-and-recent-business-highlights-for-first-quarter-fiscal-year-2022\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-03T12:31:01+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210903005055r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-reports-financial-results-and-recent-business-highlights-for-first-quarter-fiscal-year-2022\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-reports-financial-results-and-recent-business-highlights-for-first-quarter-fiscal-year-2022\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ImmunoPrecise Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2022","datePublished":"2021-09-03T12:31:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-reports-financial-results-and-recent-business-highlights-for-first-quarter-fiscal-year-2022\/"},"wordCount":387,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-reports-financial-results-and-recent-business-highlights-for-first-quarter-fiscal-year-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210903005055r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-reports-financial-results-and-recent-business-highlights-for-first-quarter-fiscal-year-2022\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-reports-financial-results-and-recent-business-highlights-for-first-quarter-fiscal-year-2022\/","name":"ImmunoPrecise Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2022 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-reports-financial-results-and-recent-business-highlights-for-first-quarter-fiscal-year-2022\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-reports-financial-results-and-recent-business-highlights-for-first-quarter-fiscal-year-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210903005055r1&sid=flmnd&distro=nx&lang=en","datePublished":"2021-09-03T12:31:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-reports-financial-results-and-recent-business-highlights-for-first-quarter-fiscal-year-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-reports-financial-results-and-recent-business-highlights-for-first-quarter-fiscal-year-2022\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-reports-financial-results-and-recent-business-highlights-for-first-quarter-fiscal-year-2022\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210903005055r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210903005055r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-reports-financial-results-and-recent-business-highlights-for-first-quarter-fiscal-year-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ImmunoPrecise Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2022"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/534313","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=534313"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/534313\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=534313"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=534313"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=534313"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}